Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
419 Currently, a spectrum of approaches ranging from traditional machine learning methods to deep learning models has been applied to integrate pathological imaging, molecular subtyping, and clinical information, enabling accurate prediction of resistance outcomes and tumor recurrence risk
Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
14 Nacuity is developing NPI-002 (diNACA), an analog to NPI-001, as an anticataract agent
These findings indicate that immunocompromised infants may be at considerably heightened risk of probiotic-associated sepsis
